Omada Health Q1 revenue jumps 42% on member growth, beats estimates

Omada Health

07/05/2026 21:43

Overview

US virtual healthcare provider's Q1 revenue rose 42% yr/yr, beating analyst expectations

Adjusted EBITDA for Q1 turned positive and beat analyst expectations

Total members surpassed one million, up 51% yr/yr, as company expanded PBM partnerships

Outlook

Omada Health sees 2026 revenue between $322 mln and $330 mln, up from prior $312 mln-$322 mln range

Company expects 2026 adjusted EBITDA of $14 mln to $20 mln, up from prior $7 mln-$15 mln range

Omada Health cites expanded PBM partnerships and GLP-1 access as drivers of future growth

Result Drivers

MEMBER GROWTH - Co said total members rose 51% yr/yr to 1.02 mln, supporting revenue growth

PBM PARTNERSHIPS - Co expanded distribution by joining Optum Rx’s Weight Engage portfolio and now partners with all three leading PBMs

GLP-1 PROGRAMS - Co said expanded access to GLP-1 and anti-obesity medications, and clinical results from its GLP-1 Care Track, supported growth

Company press release: ID:nGNX8hH3SM

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$78 mln
$74.04 mln (11 Analysts)
Q1 Net Income
-$3 mln
Q1 Adjusted EBITDA
Beat
$1 mln
-$2.88 mln (11 Analysts)
Q1 Adjusted Gross Margin
64.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Omada Health Inc is $18.00, about 13.5% above its May 6 closing price of $15.86

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)